Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Foresight Diagnostics Launches SHORTEN-ctDNA Trial to Personalize DLBCL Treatment and Reduce Toxicity

NextEdge Admin

06 Dec 2024

2 min 24 sec

diffuse large B-cell lymphoma,ctDNA testing,MRD

Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection, has launched SHORTEN-ctDNA, a clinical trial at Columbia University aimed at advancing personalized treatment for diffuse large B-cell lymphoma (DLBCL). The study will explore how the Foresight CLARITY™ platform can enable real-time treatment optimization through ctDNA analysis.

Currently, standard care for newly diagnosed DLBCL involves six cycles of rituximab and chemotherapy, a uniform approach that does not account for individual patient response. This regimen may lead to unnecessary treatment exposure for some patients, increasing the risk of side effects without improving outcomes. SHORTEN-ctDNA seeks to address this by evaluating whether patients who achieve early ctDNA clearance can safely receive fewer chemotherapy cycles while maintaining long-term survival.

“PET scans, our current standard for monitoring lymphoma, often provide inconsistent results, limiting their utility for real-time decision-making,” explained David Kurtz, MD, PhD, Chief Medical Officer and Head of Research at Foresight Diagnostics. “Foresight CLARITY offers a more dynamic and sensitive tool, enabling tailored treatment adjustments based on a patient’s unique response.”

The trial will enroll 32 newly diagnosed DLBCL patients. After three cycles of R-CHOP or pola-R-CHP therapy, patients will undergo ctDNA testing. MRD-positive patients will continue standard treatment, while MRD-negative patients will de-escalate to rituximab monotherapy for their final cycles.

“By leveraging next-generation ctDNA technology, this study aims to identify early responders, reduce treatment duration, minimize toxicity, and improve quality of life,” said Hua-Jay Cherng, MD, Principal Investigator at Columbia University.